These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34034268)

  • 1. Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites.
    Sharma P; Puri P; Bansal N; Singla V; Kumar A; ShriHari AA; Arora A
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e499-e504. PubMed ID: 34034268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients With Cirrhosis: Expert Review.
    Flamm SL; Wong F; Ahn J; Kamath PS
    Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2707-2716. PubMed ID: 36075500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
    Garcia-Tsao G; Abraldes JG; Rich NE; Wong VW
    Gastroenterology; 2024 Jan; 166(1):202-210. PubMed ID: 37978969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terlipressin vs Midodrine Plus Octreotide for Hepatorenal Syndrome-Acute Kidney Injury: A Propensity Score-Matched Comparison.
    Gonzalez SA; Chirikov VV; Wang WJ; Huang X; Jamil K; Simonetto DA
    Clin Transl Gastroenterol; 2023 Dec; 14(12):e00627. PubMed ID: 37622521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatorenal Syndrome With Acute Kidney Injury: Diagnosis and Medical Management.
    Erstad BL
    Ann Pharmacother; 2024 Feb; 58(2):156-164. PubMed ID: 37271967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Observation of the therapeutic and characteristic effects of terlipressin on refractory cirrhotic ascites].
    Xing F; Li S; Zhang JJ; Sun CY; Huang JR; Gao ZL; Zhu TT; Zhao Q; Zhang H; Liu CH
    Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):982-988. PubMed ID: 31941260
    [No Abstract]   [Full Text] [Related]  

  • 7. Standardized approach of albumin, midodrine and octreotide on hepatorenal syndrome treatment response rate.
    Hiruy A; Nelson J; Zori A; Morelli G; Cabrera R; Kamel A
    Eur J Gastroenterol Hepatol; 2021 Jan; 33(1):102-106. PubMed ID: 32243349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midodrine reduces new-onset acute kidney injury and hyponatremia in children with cirrhosis and ascites awaiting liver transplantation: Results from an open-label RCT.
    Ashritha A; Lal BB; Khanna R; Sood V; Sood AK; Alam S
    J Pediatr Gastroenterol Nutr; 2024 Feb; 78(2):350-359. PubMed ID: 38374552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial.
    Solà E; Solé C; Simón-Talero M; Martín-Llahí M; Castellote J; Garcia-Martínez R; Moreira R; Torrens M; Márquez F; Fabrellas N; de Prada G; Huelin P; Lopez Benaiges E; Ventura M; Manríquez M; Nazar A; Ariza X; Suñé P; Graupera I; Pose E; Colmenero J; Pavesi M; Guevara M; Navasa M; Xiol X; Córdoba J; Vargas V; Ginès P
    J Hepatol; 2018 Dec; 69(6):1250-1259. PubMed ID: 30138685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study.
    Hamdy H; ElBaz AA; Hassan A; Hassanin O
    J Clin Gastroenterol; 2014 Feb; 48(2):184-8. PubMed ID: 23842215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial.
    Stine JG; Wang J; Cornella SL; Behm BW; Henry Z; Shah NL; Caldwell SH; Northup PG
    Ann Hepatol; 2018 Mar; 17(2):300-306. PubMed ID: 29469046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study.
    Yosry A; Soliman ZA; Eletreby R; Hamza I; Ismail A; Elkady MA
    Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):345-351. PubMed ID: 30312183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
    Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
    Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Terlipressin in the management of adults with hepatorenal syndrome-acute kidney injury (HRS-AKI).
    Kulkarni AV; Lee J; Reddy KR
    Expert Rev Gastroenterol Hepatol; 2023; 17(11):1067-1079. PubMed ID: 37856367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
    Singh V; Dhungana SP; Singh B; Vijayverghia R; Nain CK; Sharma N; Bhalla A; Gupta PK
    J Hepatol; 2012 Feb; 56(2):348-54. PubMed ID: 21749847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure.
    Velez JC; Kadian M; Taburyanskaya M; Bohm NM; Delay TA; Karakala N; Rockey DC; Nietert PJ; Goodwin AJ; Whelan TP
    Nephron; 2015; 131(3):191-201. PubMed ID: 26485256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term mortality in patients with cirrhosis of the liver and acute kidney injury: A prospective observational study.
    Kumar U; Kumar R; Jha SK; Jha AK; Dayal VM; Kumar A
    Indian J Gastroenterol; 2020 Oct; 39(5):457-464. PubMed ID: 33175368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis.
    Dong T; Aronsohn A; Gautham Reddy K; Te HS
    Dig Dis Sci; 2016 Dec; 61(12):3621-3626. PubMed ID: 27655104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Cavallin M; Kamath PS; Merli M; Fasolato S; Toniutto P; Salerno F; Bernardi M; Romanelli RG; Colletta C; Salinas F; Di Giacomo A; Ridola L; Fornasiere E; Caraceni P; Morando F; Piano S; Gatta A; Angeli P;
    Hepatology; 2015 Aug; 62(2):567-74. PubMed ID: 25644760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
    Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
    Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.